FDA Approval - Nitroglycerin Ointment
Released
Released
Announcement PDF
ASX Release
Nitroglycerin Ointment
FDA approved in United States
Melbourne, Australia; 4 December 2024: Acrux Limited (ASX:ACR) (‘Acrux’ or the
‘Company’) is pleased to announce that the US Food and Drug Administration (‘FDA’) has
approved the Company’s sixth ANDA, a generic version of Rectiv® (Nitroglycerin Ointment,
0.4%).
Key Highlights:
• Nitroglycerin Ointment, 0.4% is indicated for the treatment of moderate to severe
pain associated with chronic anal fissure
• Annual addressable market sales for the product are growing and now
exceeds US$23 million 1
• The announcement marks Acrux’s sixth topical ANDA to be approved by the FDA
The ANDA is a generic version of Rectiv® Ointment (Nitroglycerin Ointment, 0.4%) which is a
topical treatment for moderate to severe pain due to anal fissure. The FDA has notified Acrux
that the submission has been approved.
In the United States, annual sales generated by the branded product and a generic competitor
(with which Acrux’s generic will compete) exceeded USD$23 million and 47,000 packs based
on sales reported by IQVIA1.
Acrux CEO and Managing Director, Michael Kotsanis said:
“We are very pleased to receive FDA approval for another ANDA product which has been
developed in house by the Acrux R&D team. This approval again demonstrates the
capability of the Acrux team to execute the Company’s strategy to develop our pipeline of
topical products.”
Authorised by the Board of Directors.
1 IQVIA August 2024. Product sales for previous twelve months.
For more information, please contact
Michael Kotsanis
Acrux Limited
CEO & Managing Director
P: + 61 3 8379 0100
E: michael.kotsanis@acrux.com.au
About Acrux
Acrux is a specialty pharma company with a successful track record of developing and
commercialising a pipeline of topically applied pharmaceutical products. Drawing on 25 years
of experience, Acrux has successfully marketed through licensees a number of products
worldwide with emphasis on the United States. Acrux is formulating and developing a range
of topical generic products by leveraging its highly skilled workforce, on-site laboratories, GMP
manufacturing suite, technical, clinical and commercial experience to bring affordable
products to market. Acrux encourages collaboration and is well positioned to discuss
commercial partnering and product development opportunities.
For further information on Acrux, visit www.acrux.com.au
Share your feedback
Discover